Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| BFRG | PRESS-RELEASE | bullish | 7/10 | BullFrog AI announced a commercial feasibility agreement with a top 5 global pharmaceutical company to identify drug tar | Apr 13, 2026 |
| IMA | PRESS-RELEASE | bearish | 6/10 | ImageneBio (IMA) announced a $30 million private placement led by Coastlands Capital, with proceeds aimed at advancing i | Apr 13, 2026 |
| OCUL | PRESS-RELEASE | bullish | 8/10 | Ocular Therapeutix presented additional Week 52 post-hoc data from its SOL-1 Phase 3 trial for AXPAXLI, an investigation | Apr 13, 2026 |
| SYRE | PRESS-RELEASE | bullish | 8/10 | Spyre Therapeutics announced positive 12-week induction data from Part A of its Phase 2 SKYLINE trial, showing SPY001 ac | Apr 13, 2026 |
| TLX | PRESS-RELEASE | bullish | 7/10 | Telix Pharmaceuticals announced a strategic collaboration with Regeneron to co-develop and co-commercialize next-generat | Apr 13, 2026 |
| REGN | PRESS-RELEASE | bullish | 7/10 | Regeneron and Telix announced a collaboration to co-develop and co-commercialize next-generation radiopharmaceutical the | Apr 13, 2026 |
| REGN | PRESS-RELEASE | bullish | 7/10 | Regeneron and Sanofi announced European Commission approval of Dupixent for children aged 2 to 11 years with moderate-to | Apr 13, 2026 |
| BNTX | PRESS-RELEASE | bullish | 8/10 | BioNTech announced positive Phase 2 results for trastuzumab pamirtecan in advanced endometrial cancer, showing a 47.9% c | Apr 11, 2026 |
| MESO | PRESS-RELEASE | bullish | 8/10 | Mesoblast received FDA clearance to proceed directly into a registrational trial for Ryoncil® (remestemcel-L-rknd) in Du | Apr 10, 2026 |
| LYB | PRESS-RELEASE | neutral | 2/10 | LyondellBasell announced the internet availability of its proxy materials and annual report for the 2026 annual sharehol | Apr 10, 2026 |
| PHGE | PRESS-RELEASE | bullish | 7/10 | BiomX (PHGE) has completed the acquisition of Zorronet, an AI-powered command-and-control software company, from Water.i | Apr 10, 2026 |
| ANVS | PRESS-RELEASE | mixed | 6/10 | Annovis Bio reported a wider-than-expected EPS loss of $-0.39 (vs $-0.36 est) with no revenue, but secured $10M in gross | Apr 10, 2026 |
| IRD | PRESS-RELEASE | neutral | 4/10 | Opus Genetics announced that three abstracts, including full Phase 3 results from the VEGA-3 trial for presbyopia and da | Apr 10, 2026 |
| AKTX | PRESS-RELEASE | bullish | 6/10 | Akari Therapeutics announced a strategic partnership with WuXi XDC to accelerate development of its antibody drug conjug | Apr 9, 2026 |
| ONCO | PRESS-RELEASE, 425 | bullish | 6/10 | Onconetix highlighted the delivery of the first Vinci-equipped humanoid robot by Realbotix, its pending acquisition targ | Apr 9, 2026 |
| KYTX | PRESS-RELEASE | bullish | 8/10 | Kyverna Therapeutics announced upcoming oral presentations at the AAN Annual Meeting detailing primary analysis from its | Apr 9, 2026 |
| ELAB | PRESS-RELEASE | bullish | 6/10 | PMGC Holdings' subsidiary AGA Precision Systems secured a second long-term agreement (LTA) with a confidential Tier 1 ae | Apr 9, 2026 |
| IFRX | PRESS-RELEASE | bullish | 7/10 | InflaRx announced new in vitro data showing izicopan does not exhibit time-dependent inhibition of CYP3A4, a key enzyme | Apr 9, 2026 |
| CCCC | PRESS-RELEASE | bullish | 7/10 | C4 Therapeutics announced a collaboration with Roche to develop degrader-antibody conjugates (DACs) for two oncology tar | Apr 9, 2026 |
| IVVD | PRESS-RELEASE | mixed | 6/10 | Invivyd announced progress in its Phase 3 DECLARATION study for VYD2311, including a pre-specified upsizing by ~500 subj | Apr 9, 2026 |
| INDV | PRESS-RELEASE | neutral | 1/10 | Indivior Pharmaceuticals Inc. announced it will report its Q1 2026 results on April 30. | Apr 9, 2026 |
| HCM | PRESS-RELEASE | mixed | 6/10 | HUTCHMED announced upcoming presentations of preclinical data for HMPL-A580, a first-in-class antibody-targeted therapy | Apr 8, 2026 |
| MGNX | PRESS-RELEASE | bullish | 7/10 | MacroGenics announced that the FDA has lifted the partial clinical hold on its Phase 2 LINNET study of lorigerlimab for | Apr 8, 2026 |
| CRNX | PRESS-RELEASE | neutral | 1/10 | Crinetics Pharmaceuticals, Inc. announced it will report its Q1 2026 results on May 7, 2026. | Apr 8, 2026 |
| ICCC | PRESS-RELEASE | mixed | 6/10 | ImmuCell reported preliminary Q1 2026 sales of $10.4M, up 28.4% YoY, driven by a 38.5% surge in Tri-Shield® sales. Inter | Apr 8, 2026 |
| PRQR | PRESS-RELEASE | neutral | 4/10 | ProQR Therapeutics provided a pipeline update highlighting progress on its lead program AX-0810, with target engagement | Apr 8, 2026 |
| TOMZ | PRESS-RELEASE | bullish | 7/10 | TOMI Environmental Solutions reported preliminary unaudited revenue of $1.7M for Q1 2026, a 67% sequential increase from | Apr 8, 2026 |
| MESO | PRESS-RELEASE | bullish | 7/10 | Mesoblast highlighted its commercial strategy as Ryoncil® nears $100M in net revenue since launch, announced the close o | Apr 8, 2026 |
| CUE | PRESS-RELEASE | bullish | 6/10 | Cue Biopharma announced it will receive a $7.5 million preclinical milestone payment from Boehringer Ingelheim in May 20 | Apr 8, 2026 |
| ASND | PRESS-RELEASE | bullish | 8/10 | Ascendis Pharma announced Week 52 data from its Phase 2 COACH trial showing that the combination of TransCon CNP and Tra | Apr 8, 2026 |